Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
- Sponsor
- The University of Hong Kong
- Study ID
- NCT07022535
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cancer
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- KELIM — DIAGNOSTIC_TEST(i) Patients with KELIM \>=1 will receive radiological assessment and undergo interval debulking surgery if the disease is operable. (ii) Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery
- Carboplatin plus Paclitaxel — DRUGChemotherapy as neaodjuvant chemotherapy
- Interval debulking surgery — PROCEDUREInterval debulking surgery
Study Details
About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients.
Key Dates
- First listed
- Jun 15, 2025
- Start date
- May 28, 2024
- Status verified
- Jun 2025
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2025
Study Design
- Enrollment
- 18 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Personalised managementPatients will be managed based on CA-125 ELIMination Rate Constant K (KELIM) at the neoadjuvant setting.
Primary Outcome Measure
Complete resection (CC0) rate [ Time Frame: Up to 24 months ]
Central Contacts
- Lesley Lau, MPhil+852 22554265
- Iris Tang+852 22554265
Find similar trials
Related Studies
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruiting · M.D. Anderson Cancer Center · Miami, Florida
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood SamplesRecruiting · Stanford University · Stanford, California
- Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic AnalysisRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland